

## **Hypoperfusion Profiles in outcome after Endovascular Therapy for Isolated Internal Carotid Artery Occluded Patients**

Feina Shi<sup>1</sup>, MD; Yigang Chen<sup>1</sup>, MD; Xu Zheng<sup>1</sup>, MD; Yun Jiang<sup>1</sup>, MD; Ziqi Xu<sup>2</sup>, MD; En Wang<sup>3</sup>, MD; Changzhu Wu<sup>3</sup>, MD; Chuan Xu<sup>1</sup>, MD; Qingqing Gao<sup>1</sup>, MD; Xi Hu<sup>4</sup>, MS; Jinhua Zhang<sup>1</sup>, MD

1. Department of Neurology, Sir Run Run Shaw Hospital of Zhejiang University, School of Medicine, Hangzhou, China

2. Department of Neurology, the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China

3. Department of Neurology, Taizhou Hospital of Zhejiang Province, Taizhou, China

4. Department of Radiology, Sir Run Run Shaw Hospital of Zhejiang University, School of Medicine, Hangzhou, China

**\*Corresponding author** : Jinhua Zhang M.D. Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China. 310009.

Email: zhangjinhua@zju.edu.cn

**Short title:** Hypoperfusion profiles in patients with iCAO

**Word count:** 4971 words

## **Abbreviations**

iCAO: isolated internal carotid artery occlusion; AIS: acute ischemic stroke; NIHSS: National Institutes of Health Stroke Scale; OPT: onset-to-puncture time; HT: hemorrhagic transformation; EVT: endovascular treatment; LVO: large vessel occlusion; CTA: CT angiography; CTP: CT perfusion; ROC: receiver operating characteristic; AUC: area under the curve; mRS: modified Rankin Scale score; LAA: large-artery atherosclerosis; CE: cardioembolism; TICI : Thrombolysis in Cerebral Infarction; CBF: cerebral blood flow;  $T_{max}$ : time-to-peak of the residual function

## Abstract

**Background:** Patients with acute symptomatic isolated internal carotid artery occlusions (iCAO), also known as ICA-I occlusion, frequently presented with minor neurological deficits. However, they remained at risk for subsequent neurological deterioration even after intravenous thrombolysis. The efficacy of endovascular treatment (EVT) in iCAO patients remains uncertain. Recently, some retrospective studies revealed EVT for acute iCAO was safe and might confer potential benefits. Our aim was to identify the hypoperfusion profiles associated with neurological deterioration and functional outcome following EVT in iCAO patients.

**Methods:** We performed a multi-center, real-world cohort study involving acute symptomatic iCAO patients who underwent EVT from August 2018 to February 2024 across 3 stroke centers. Hypoperfusion profiles were assessed using  $T_{\max}$  volumes (>4s, >6s, >8s, and >10s) and  $T_{\max}$  mismatch ratios (>10s/>8s, >10s/>6s, >10s/>4s, >8s/>6s, >8s/>4s, and >6s/>4s). Neurological deterioration was defined as an increase of  $\geq 4$  points in the NIHSS score prior to EVT. Good outcome was defined as modified Rankin Score 0 - 1 at 90 days.

**Results:** A total of 63 patients were included in the final analysis. Multivariable models showed that a lower  $T_{\max}$  ratio of >6s/>4s was an independent predictor for increased risk of neurological deterioration (OR, 0.003; 95% CI: 0.000-0.133;  $P = 0.003$ ) and was associated with a better outcome following EVT (OR, 0.066; 95% CI: 0.005-0.874;  $P = 0.039$ ) after adjustment. The optimal threshold for the  $T_{\max}$  >6s/>4s ratio was identified as 0.5.

**Conclusions:** A perfusion defect severity ratio of  $T_{\max}$  >6s/>4s less than 0.5 might indicate the likelihood of neurological deterioration, yet it would be associated with achieving a good outcome following EVT for iCAO patients. The hypoperfusion profile characterized by a  $T_{\max}$  >6s/>4s might be useful to the neurointerventionists for facilitating appropriate patient triage and guiding prognosis for EVT in iCAO patients.

**Keywords:** acute ischemic stroke, symptomatic isolated internal carotid artery occlusion,  $T_{\max}$  mismatch ratio, neurological deterioration; outcome

## Introduction

Isolated internal carotid artery occlusion (iCAO), without associated occlusions of the circle of Willis (ie, without T-shaped, L-shaped, or tandem occlusions), was not rare among acute ischemic stroke (AIS) patients, accounting for approximately 10%-20% of all carotid occlusions<sup>1-3</sup>. Although many clinical trials have suggested the benefit of endovascular treatment (EVT) for AIS patients with intracranial large vessel occlusion (LVO)<sup>4,5</sup>, those patients with iCAO have often been overlooked. Given the lack of evidence derived from randomized trials, the potential benefits of EVT for the AIS patients only with iCAO remains unclear. Recently, several non-randomized studies have demonstrated the feasibility, safety, and potential benefits of EVT for iCAO patients<sup>6,7</sup>.

Clinical severity among patients with iCAO is highly variable and they frequently present with minor neurological deficits in part as a function of collateral circulation<sup>8</sup>. The iCAO patients often exhibit extensive hypoperfusion on imaging, indicating insufficient cerebral perfusion despite good arterial collateral circulation. The cerebral collateral cascade, facilitating the successful delivery of blood flow to ischemic tissue, would influence the clinical and radiological outcomes in AIS patients<sup>9</sup>. For iCAO patients allowing blood flow to the middle cerebral artery through the circle of Willis, the arterial collateral circulation on CT angiography (CTA) seemed adequate. However, the extensive hypoperfusion observed in iCAO patients still indicates inadequacy of collateral supply. Thus, the extensive hypoperfusion observed in iCAO patients might be the result of the complex vascular mechanisms, rather than solely by arterial collaterals. It has been demonstrated that perfusion delay lesions would be related with neurological deterioration<sup>10</sup>. In previous studies, early neurological deterioration was reported in 15-30% of these iCAO patients even after intravenous thrombolysis or when presenting with mild symptoms initially<sup>8,11</sup>. Therefore, it is crucial to identify iCAO patients who are at high risk for neurological deterioration, as they are the individuals most likely to benefit from these promising therapies, such as EVT. CT perfusion (CTP) is increasingly applied to quantitative evaluation of perfusion status of the whole brain in AIS patients. In clinical trials, CTP has been used to select optimal candidates who would benefit from reperfusion therapy. The characteristics of hypoperfused

brain regions and their relationship with outcome after EVT for iCAO patients still remain unclear. In previous studies, hypoperfusion profiles evaluated with time-to-peak of the residual function ( $T_{\max}$ ) ratios were found to be associated with infarct growth and functional outcome<sup>12-14</sup>.

In this study, we aimed to explore hypoperfusion profiles of iCAO associated with neurological deterioration. We also evaluated the relationship between hypoperfusion profiles and functional outcome after EVT in iCAO patients.

## **Material and Methods**

### **Ethics Statement**

The investigations have been conducted according to the principles expressed in the Declaration of Helsinki. The protocol was approved by the local human ethics committees. Written informed consent was obtained from all patients or their designated proxy to confirm the acceptance of reperfusion therapy.

### **Patients**

The current multi-center real-world retrospective cohort study reviewed acute ischemic stroke patients who were treated with EVT from August 2018 to February 2024 from 3 stroke centers. Then, patients were included if they (1) had a recent diagnosis (<2 weeks) of AIS confirmed with by DWI or CT; (2) underwent CTP before EVT treatment; and (3) had ipsilateral ICAO without occlusion of the ipsilateral intracranial large arteries, such as C7 segment of ICA, M1–M2 segments of the middle cerebral artery, A1-A2 segments of the anterior cerebral artery, P1-P2 segments of the posterior cerebral artery. Patients who had poor image quality due to motion artifacts or incomplete images were excluded.

### **Clinical data**

Baseline clinical variables and radiologic data were recorded, including demographics, risk factors (smoking, hypertension, diabetes mellitus, hyperlipidaemia, a history of stroke/TIA and atrial fibrillation), prior usage of antiplatelet/ anticoagulants, intravenous thrombolysis, onset-to-puncture time (OPT), baseline National Institutes of Health Stroke Scale (NIHSS) score. The stroke etiologies were determined as large-artery atherosclerosis (LAA), cardioembolism (CE), dissection, other causes or undetermined<sup>7</sup>. Neurological deterioration was defined as an increase of  $\geq 4$  points in the NIHSS score before EVT<sup>15</sup>. Patients were then dichotomized into good outcome (mRS score of  $\leq 1$ ) and poor outcome (mRS score of  $>1$ ) at 90 days.

### **Imaging Analysis**

The occlusion location was determined on reconstructed CTA images derived from CTP. Recanalization after EVT was assessed on DSA images as modified TIC1 grades  $\geq 2b$ , and hemorrhagic transformation (HT) was assessed on follow-up NCCT according to the second European-Australasian Acute Stroke Study (ECASS II)<sup>16</sup>. Pretreatment relative cerebral blood flow (CBF) of less than 30% at CTP was used to calculate the baseline infarct core volume, and  $T_{max}$  was used for volumetric measurement of pretreatment hypoperfusion lesion profiles. The hypoperfused brain tissue volumes were automatically measured using  $T_{max}$  thresholds of  $>10s$ ,  $>8s$ ,  $>6s$ , and  $>4s$ .  $T_{max}$  ratios of  $>10s/>8s$ ,  $>10s/>6s$ ,  $>10s/>4s$ ,  $>8s/>6s$ ,  $>8s/>4s$ , and  $>6s/>4s$  were considered  $T_{max}$  mismatch ratios. All imaging analyses were assessed by the independent experienced neuroradiologist.

### **Statistical Analysis**

Continuous variables were reported as medians with interquartile range, and categorical variables were reported as proportions. For categorical variables, Chi-Square test was used to compare differences among groups. For continuous variables, Man-Whitney U test was used to compare the difference between two groups. The receiver operating characteristic (ROC) analyses were performed to assess the discriminative ability and area under the curve (AUC) was calculated. Optimal cutoff values were derived from ROC curves, and sensitivity and specificity were calculated on the basis of these best cutoff values. The variables with P values  $<0.1$  at univariable analysis were included in the multivariable models. Multivariable regression analysis was performed using the method of backward. All statistical analyses were performed using SPSS, Version 22.0 (IBM, Armonk, New York). P value  $< 0.05$  was considered statistically significant.

## Results

### Patient Characteristics

A total of 65 patients met the inclusion criteria and 2 patients were excluded due to poor image quality. Finally, a total of 63 patients with AIS attributable to iCAO were included in final analysis, with a median age of 66 (55-72) years, a median NIHSS score of 9 (6-14), and a median OPT of 993 (660-2001) min. A median of baseline infarct core (CBF <30%) volume was 0.9 (0.0-14.7) mL, and a median of  $T_{\max}>6s$  volume was 142.6 (52.8-234.0) mL.

Intravenous thrombolysis was administered to 7 (11.1%) patients. Neurological deterioration occurred prior to EVT in 34 (54.0%) iCAO patients. Among these, 59 (93.7%) iCAO patients achieved successful recanalization, and hemorrhagic transformation was observed in 11(17.5%) iCAO patients after EVT.

### Association of hypoperfusion profiles with neurological deterioration in iCAO patients

As show in Table 1, the iCAO patients with neurological deterioration had a significantly lower NIHSS score (median 7 vs 11,  $P<0.001$ ) and a lower ASPECTS score (median 8 vs 9,  $P=0.023$ ) than those without neurological deterioration. The iCAO patients with neurological deterioration had a significantly lower baseline infarct core volume (median 0.0mL vs 8.3mL,  $P=0.006$ ). Compared to those without neurological deterioration, iCAO patients with neurological deterioration exhibited significantly lower volumes of  $T_{\max}>6s$  (median 105.7mL vs 197.4mL,  $P=0.034$ ),  $T_{\max}>8s$  (median 32.1mL vs 111.0mL,  $P=0.021$ ),  $T_{\max}>10s$  (median 6.4mL vs 40.7 mL,  $P=0.003$ ). However, there was no significant association between  $T_{\max}>4s$  volume and neurological deterioration. Furthermore,  $T_{\max}$  mismatch ratios, including  $T_{\max}$  ratios of  $>10s/8s$  (median 0.3 vs 0.6,  $P<0.001$ ),  $>10s/>6s$  (median 0.1 vs 0.3,  $P=0.001$ ),  $>10s/>4s$  (median 0.0 vs 0.1,  $P=0.001$ ),  $>8s/>6s$  (median 0.4 vs 0.6,  $P=0.004$ ),  $>8s/>4s$  (median 0.1 vs 0.3,  $P=0.003$ ),  $>6s/>4s$  (median 0.4 vs 0.6,  $P=0.001$ ), were significantly lower in iCAO patients with neurological deterioration compared to those without neurological deterioration.

Then, the baseline NIHSS score, ASPECTS score, baseline infarct core volume, and alongside with each hypoperfusion profile with  $P < 0.1$  from the univariable analyses (i.e., the volume of  $T_{\max}>6s$ ,  $T_{\max}>8s$ ,  $T_{\max}>10s$ , and  $T_{\max}$  ratios



---

of  $>10s/8s$ ,  $>10s/6s$ ,  $>10s/4s$ ,  $>8s/6s$ ,  $>8s/4s$ ,  $>6s/4s$ ), were included in a separate multivariable regression analysis. Multivariable models showed that  $T_{max}$  ratio of  $>6s/4s$  (OR, 0.003; 95% CI: 0.000-0.133;  $P = 0.003$ ),  $T_{max}$  ratio of  $>8s/4s$  (OR, 0.010; 95% CI: 0.000-0.510;  $P = 0.022$ ), and the volume of  $T_{max}>6s$  (OR, 0.994; 95% CI: 0.987-1.000;  $P = 0.049$ ) were all independently associated with neurological deterioration after adjustment, respectively. The other hypoperfusion profiles did not emerge as independent factors of neurological deterioration (all  $P>0.05$ ). The ROC analyses indicated that the optimal cutoff, AUC, sensitivity, specificity and Youden index for  $T_{max}$  ratio of  $>6s/4s$  in predicting neurological deterioration were 0.5, 79.3%, 70.6% and 49.9%, respectively. For  $T_{max}$  ratio of  $>8s/4s$ , these values were 0.2, 65.5%, 76.5%, and 42.0%. And these values were 164.2mL, 65.5%, 73.5%, and 39.0% for  $T_{max}>6s$  (Table 2).

### **Association of hypoperfusion profiles with functional outcome in iCAO patients receiving EVT**

Among 57 iCAO patients with pre-stroke mRS  $<1$ , good outcome (i.e., 90-day mRS  $\leq 1$ ) after EVT was achieved in 23(40.4%) patients. As illustrated in Table 3, the iCAO patients with good outcome had a significantly lower NIHSS score (median 8 vs 11,  $P=0.010$ ).  $T_{max}$  volumes at  $T_{max}>6s$  (median 55.7mL vs 164.2mL,  $P=0.006$ ),  $T_{max}>8s$  (median 14.7mL vs 66.4mL,  $P=0.007$ ), and  $T_{max}>10s$  (median 3.3mL vs 19.9mL,  $P=0.009$ ) were significantly lower in iCAO patients with good outcome than those with poor outcome. The volume of  $T_{max}>4s$  was inclined to be lower in iCAO patients with good outcome compared to those with poor outcome (median 189.3mL vs 309.0mL,  $P=0.053$ ).  $T_{max}$  mismatch ratios of  $>10s/4s$  (median 0.0 vs 0.1,  $P=0.034$ ),  $>8s/4s$  (median 0.1 vs 0.2,  $P=0.033$ ),  $>6s/4s$  (median 0.4 vs 0.5,  $P=0.037$ ) were also significantly lower in iCAO patients with good outcome than those with poor outcome. There were no significant differences between these two groups in baseline infarct core volume, nor in the other hypoperfusion profiles ( $T_{max}$  ratios of  $>10s/8s$ ,  $>10s/6s$ ,  $>8s/6s$ ). We found that neurological deterioration was not related with the functional outcome after EVT in iCAO patients. There were no significant differences in recanalization rates, hemorrhagic transformation following EVT, or stroke etiologies between patients with good outcome and poor outcome.

Then, the baseline NIHSS score, ASPECTS score, and each hypoperfusion profile with  $P < 0.1$  from the univariable analysis (i.e., the volume of  $T_{\max} > 4s$ ,  $T_{\max} > 6s$ ,  $T_{\max} > 8s$ ,  $T_{\max} > 10s$ , and  $T_{\max}$  ratios of  $>10s/6s$ ,  $>10s/>4s$ ,  $>8s/>4s$ ,  $>6s/>4s$ ) were incorporated into a separate multivariable regression model. Multivariable models indicated that the volumes of  $T_{\max} > 4s$  (OR, 0.996; 95% CI: 0.992-1.000;  $P = 0.038$ ),  $T_{\max} > 6s$  (OR, 0.993; 95% CI: 0.988-0.999;  $P = 0.016$ ), and  $T_{\max}$  ratio of  $>6s/>4s$  (OR, 0.066; 95% CI: 0.005-0.874;  $P = 0.039$ ) were all independent predictors of good outcome after EVT in iCAO patients after adjustment, respectively. The ROC analyses identified the optimal cutoff values, sensitivity, specificity and Youden index for the  $T_{\max}$  ratio of  $>6s/>4s$  in predicting functional outcome after EVT as 0.5, 55.9%, 73.9% and 29.8%, respectively. For  $T_{\max} > 4s$ , the values were 166.7mL, 91.2%, 47.8%, and 39.0%, while for  $T_{\max} > 6s$ , they were 64.9mL, 82.4%, 60.9%, 43.3% (Table 4).

## Discussion

In this multicenter real-world study, we found that a lower  $T_{max}$  ratio of  $>6s/>4s$  was an independent predictor for a higher risk of neurological deterioration before EVT, and it was independently associated with a better functional outcome after EVT for AIS patients with iCAO. A threshold of  $T_{max} >6s/>4s$  of 0.5 enabled prediction of neurological deterioration and functional outcome.

The optimal treatment strategies for iCAO patients still remain uncertain and depend on the expertise. Previous studies have provided limited data regarding EVT for acute symptomatic iCAO. According to the current AHA/ASA guideline based on large EVT clinical trials, EVT is a well-proven treatment for LVO including distal ICA and MCA<sup>5</sup>. A limited number of AIS patients with iCAO were included in those clinical trials. Some researches with small samples have indicated that EVT might be an alternative approach for symptomatic iCAO patients by mitigating the risk of neurological deterioration secondary to hemodynamic insufficiency and subsequent infarction<sup>7,17</sup>. A retrospective observational study from MR CLEAN analyzed a total of 51 iCAO patients and found that those who underwent EVT demonstrated better outcome compared to those receiving medical treatment alone<sup>6</sup>. Recently, a retrospective analysis of 45 iCAO patients from ETIS registry suggested that EVT for AIS (<2weeks) due to iCAO was associated with a high recanalization rate and a 40% rate of good functional outcome<sup>7</sup>. These results were comparable to those observed in AIS patients with intracranial occlusions following EVT. Nearly half of AIS patients undergoing EVT did not have good outcome despite successful recanalization, a phenomenon referred to as futile recanalization<sup>18</sup>. This suggested that successful recanalization might not necessarily correspond to effective reperfusion of ischemic brain tissues. The inadequate perfusion status of brain tissue would be related with futile recanalization due to the no-reflow phenomenon or reperfusion injury<sup>19,20</sup>.

It is worth exploring the role of perfusion status before EVT in facilitating appropriate triage of iCAO patients for EVT. Brain tissue-level perfusion parameters on perfusion imaging reflected the comprehensive manifestation of the arterial collateral blood flow successfully

permeated to the brain tissue and then transit to venous circulation. CTP could provide the quantitative information of cerebral perfusion, which might contribute to the selection of the optimal candidates for reperfusion therapy. The perfusion pattern in patients with iCAO characterized by a small core but a large hypoperfusion might be differ from perfusion profiles seen in AIS patients with intracranial occlusions. Good collateral circulation via the circle of Willis could maintain perfusion for the brain tissue in the affected hemisphere<sup>21</sup>. The neurological deficits would be exacerbated when hypoperfusion prolonged as a result of inadequate treatment and collateral circulation failure<sup>22</sup>. The iCAO patients with neurological symptoms implying hypoperfusion might due to collapsed collateral circulation. Therefore, tissue-level perfusion status measured with CTP might be helpful in refining the selection of EVT-eligible iCAO patients.

$T_{max}$  mismatch ratios offer a comprehensive evaluation of perfusion delay status of brain tissue, which might be useful for selection of iCAO patients eligible for endovascular intervention. For AIS patients with intracranial LVO, previous studies showed that the ratio of  $T_{max} > 10s / > 6s$  was associated with fast infarct progression and functional outcome<sup>12,14</sup>. And a lower  $T_{max}$  ratio of  $> 10 s / > 6 s$  was found to be associated with intracranial atherosclerotic LVO characterized as chronic hypoperfusion<sup>14,23</sup>. A previous study has demonstrated that a profile of  $T_{max} > 4 s / > 6s$  with  $\geq 2$  was an independent indicator of underlying intracranial atherosclerotic disease<sup>24</sup>. The threshold of  $T_{max} > 4 s$  has been defined as brain tissues likely exhibiting benign oligemic, whereas  $T_{max} > 6 s$  signifies brain tissues at risk, commonly referred to as penumbral lesions.  $T_{max} > 10 s$  is indicative of brain tissues experiencing malignant hypoperfusion<sup>14,23,24</sup>. For patients with iCAO, the perfusion status might be different from that observed in AIS patients with intracranial LVO. In our study, we observed that a perfusion profile characterized by a lower  $T_{max} > 6s / > 4s$  was independently associated with a higher rate of neurological deterioration and better functional outcome after EVT in iCAO patients, suggesting that a cutoff value of 0.5 might be optimal for EVT. Consequently, our findings might reflect the presence of clinically silent oligemic brain tissues and penumbra lesions that are at high risk for progression. However, these hypoperfused brain tissues could still be salvaged through EVT intervention, resulting in functional recovery.

There are several limitations of this study. Firstly, as this study was based on retrospective analyses, our findings might have selection bias and require prospective validation. Secondly, this multicenter study consisting of a selected population in which eligibility for EVT was decided by the local stroke teams, and lacked data from patients who did not receiving EVT were lacking. Lastly, the sample size of this study was relatively small. Future investigations into the outcomes following EVT in iCAO patients should be conducted through larger sample sizes and randomized prospective clinical trials.

### **Conclusion**

In summary, our findings have suggested perfusion defect severity ratio of  $T_{max} > 6s / > 4s$  less than 0.5 might indicate an elevated risk of neurological deterioration, yet it would be associated with achieving better outcome after EVT for iCAO patients. Therefore, the hypoperfusion profile characterized by a  $T_{max} > 6s / > 4s$  on CTP could be valuable for the neurointerventionists in facilitating appropriate patient triage and guiding prognosis for EVT in iCAO patients.

### **Disclosure**

None declared.

### **Data availability statement**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### **Sources of Funding**

This work was support by the National Natural Science Foundation of China (82402210), Natural Science Foundation of Zhejiang Province (LQ23H090014) and Medical Health

Science and Technology Program of Zhejiang Province (2023KY778).

## Reference

1. Liebeskind DS, Flint AC, Budzik RF, Xiang B, Smith WS, Duckwiler GR, Nogueira RG. Carotid I's, L's and T's: collaterals shape the outcome of intracranial carotid occlusion in acute ischemic stroke. *J Neurointerv Surg*. 2015;7:402-407. doi: 10.1136/neurintsurg-2014-011231
2. Damania D, Kung NT, Jain M, Jain AR, Liew JA, Mangla R, Koch GE, Sahin B, Miranpuri AS, Holmquist TM, et al. Factors associated with recurrent stroke and recanalization in patients presenting with isolated symptomatic carotid occlusion. *Eur J Neurol*. 2016;23:127-132. doi: 10.1111/ene.12819
3. Duloquin G, Graber M, Garnier L, Crespy V, Comby PO, Baptiste L, Mohr S, Delpont B, Guéniat J, Blanc-Labarre C, et al. Incidence of Acute Ischemic Stroke With Visible Arterial Occlusion: A Population-Based Study (Dijon Stroke Registry). *Stroke*. 2020;51:2122-2130. doi: 10.1161/strokeaha.120.029949
4. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CB, van der Lugt A, de Miquel MA, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387:1723-1731. doi: 10.1016/s0140-6736(16)00163-x
5. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e344-e418. doi: 10.1161/str.0000000000000211
6. Hoving JW, Kappelhof M, Schembri M, Emmer BJ, Berkhemer OA, Groot AED, Dippel DWJ, van Zwam WH, Coutinho JM, Marquering HA, et al. Thrombectomy for acute ischemic stroke patients with isolated distal internal carotid artery occlusion: a retrospective observational study. *Neuroradiology*. 2021;63:777-786. doi: 10.1007/s00234-020-02550-5
7. Ter Schiphorst A, Peres R, Dargazanli C, Blanc R, Gory B, Richard S, Marnat G, Sibon I, Guillon B, Bourcier R, et al. Endovascular treatment of ischemic stroke due to isolated internal carotid artery occlusion: ETIS registry data analysis. *J Neurol*. 2022;269:4383-4395. doi: 10.1007/s00415-022-11078-y

8. Ter Schiphorst A, Gaillard N, Dargazanli C, Mourand I, Corti L, Charif M, Ayrygnac X, Lippi A, Bouly S, Thibault L, et al. Symptomatic isolated internal carotid artery occlusion with initial medical management: a monocentric cohort. *J Neurol*. 2021;268:346-355. doi: 10.1007/s00415-020-10118-9
9. Faizy TD, Mlynash M, Kabiri R, Christensen S, Kuraitis GM, Mader MM, Flottmann F, Brooks G, Lansberg MG, Albers GW, et al. The Cerebral Collateral Cascade: Comprehensive Blood Flow in Ischemic Stroke. *Neurology*. 2022. doi: 10.1212/wnl.0000000000200340
10. Gwak DS, Kwon JA, Shim DH, Kim YW, Hwang YH. Perfusion and Diffusion Variables Predict Early Neurological Deterioration in Minor Stroke and Large Vessel Occlusion. *J Stroke*. 2021;23:61-68. doi: 10.5853/jos.2020.01466
11. Boulenoir N, Turc G, Henon H, Laksiri N, Mounier-Véhier F, Girard Buttaz I, Duong DL, Papassin J, Yger M, Triquenot A, et al. Early neurological deterioration following thrombolysis for minor stroke with isolated internal carotid artery occlusion. *Eur J Neurol*. 2021;28:479-490. doi: 10.1111/ene.14541
12. Seners P, Yuen N, Olivot JM, Mlynash M, Heit JJ, Christensen S, Escribano-Paredes JB, Carrera E, Strambo D, Michel P, et al. Factors Associated With Fast Early Infarct Growth in Patients With Acute Ischemic Stroke With a Large Vessel Occlusion. *Neurology*. 2023;101:e2126-e2137. doi: 10.1212/wnl.0000000000207908
13. Liu XL, Hang Y, Cao Y, Jia Z, Zhao LB, Shi HB, Liu S. Tmax profile in computed tomography perfusion-based RAPID software maps influences outcome after mechanical thrombectomy in patients with basilar artery occlusion. *J Neurointerv Surg*. 2023;15:639-643. doi: 10.1136/neurintsurg-2021-018557
14. Olivot JM, Mlynash M, Inoue M, Marks MP, Wheeler HM, Kemp S, Straka M, Zaharchuk G, Bammer R, Lansberg MG, et al. Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort. *Stroke*. 2014;45:1018-1023. doi: 10.1161/strokeaha.113.003857
15. Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. *J Neurol Neurosurg Psychiatry*. 2015;86:87-94. doi: 10.1136/jnnp-2014-308327



16. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet*. 1998;352:1245-1251. doi: 10.1016/s0140-6736(98)08020-9
17. de Castro-Afonso LH, Nakiri GS, Moretti Monsignore L, Dias FA, Aléssio-Alves FF, Rezende MT, Trivelato FP, Pontes-Neto OM, Abud DG. Endovascular Reperfusion for Acute Isolated Cervical Carotid Occlusions: The Concept of "Hemodynamic Thrombectomy". *Interv Neurol*. 2020;8:27-37. doi: 10.1159/000493021
18. Heit JJ, Mlynash M, Christensen S, Kemp SM, Lansberg MG, Marks MP, Olivot JM, Gregory AW. What predicts poor outcome after successful thrombectomy in late time windows? *J Neurointerv Surg*. 2021;13:421-425. doi: 10.1136/neurintsurg-2020-016125
19. Ter Schiphorst A, Charron S, Hassen WB, Provost C, Naggara O, Benzakoun J, Seners P, Turc G, Baron JC, Oppenheim C. Tissue no-reflow despite full recanalization following thrombectomy for anterior circulation stroke with proximal occlusion: A clinical study. *J Cereb Blood Flow Metab*. 2021;41:253-266. doi: 10.1177/0271678x20954929
20. Bai J, Lyden PD. Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. *Int J Stroke*. 2015;10:143-152. doi: 10.1111/ijss.12434
21. van Rooij WJ, Sluzewski M, Slob MJ, Rinkel GJ. Predictive value of angiographic testing for tolerance to therapeutic occlusion of the carotid artery. *AJNR Am J Neuroradiol*. 2005;26:175-178.
22. Cechetti F, Pagnussat AS, Worm PV, Elsner VR, Ben J, da Costa MS, Mestriner R, Weis SN, Netto CA. Chronic brain hypoperfusion causes early glial activation and neuronal death, and subsequent long-term memory impairment. *Brain Res Bull*. 2012;87:109-116. doi: 10.1016/j.brainresbull.2011.10.006
23. Yoshimoto T, Inoue M, Tanaka K, Koge J, Shiozawa M, Kamogawa N, Ishiyama H, Abe S, Imamura H, Kataoka H, et al. Tmax Mismatch Ratio to Identify Intracranial Atherosclerotic Stenosis-Related Large-Vessel Occlusion Before Endovascular Therapy. *J Am Heart Assoc*. 2023;12:e029899. doi: 10.1161/jaha.123.029899

24. Haussen DC, Bousslama M, Dehkharghani S, Grossberg JA, Bianchi N, Bowen M, Frankel MR, Nogueira RG. Automated CT Perfusion Prediction of Large Vessel Acute Stroke from Intracranial Atherosclerotic Disease. *Interv Neurol*. 2018;7:334-340. doi: 10.1159/000487335

## Tables

**Table 1 Comparison of Characteristics between Symptomatic Isolated Internal Carotid Artery Occlusion Patients with Neurological Deterioration**

	No Neurological Deterioration (n = 29)	Neurological Deterioration (n = 34)	P value
Age, y	67(57-78)	62(54-70)	0.142
Male	19(65.5%)	26(76.5%)	0.337
Baseline NIHSS	11(9-17)	7(5-11)	<0.001
Systolic blood pressure, mmHg	145(126-161)	143(128-157)	0.854
Diastolic blood pressure, mmHg	76(69-98)	78(72-88)	0.810
Intravenous thrombolysis	4(13.8%)	3(8.8%)	0.694
Prior antiplatelet use	7(24.1%)	4(11.8%)	0.197
Prior anticoagulants use	1(3.4%)	0(0.0%)	0.460
Risk factors			
Smoking	8(27.6%)	16(47.1%)	0.113
Hypertension	23(79.3%)	21(61.8%)	0.130
Diabetes mellitus	14(48.3%)	11(32.4%)	0.198
History of stroke or transient ischemic attack	3(10.3%)	4(11.8%)	1.000
Hyperlipidaemia	4(13.8%)	4(11.8%)	1.000
Atrial fibrillation	5(17.2%)	3(8.8%)	0.453
Baseline ASPECTS	9(8-10)	8(7-9)	0.023
Baseline perfusion lesion			
Baseline infarct core volume	8.3(0.0-25.4)	0.0(0.0-2.7)	0.006
Hypoperfusion profiles			
T <sub>max</sub> >4s, mL	342.0(159.0-473.7)	266.6(170.7-365.3)	0.270
T <sub>max</sub> >6s, mL	197.4(59.6-317.6)	105.7(48.0-179.9)	0.034
T <sub>max</sub> >8s, mL	111.0(16.3-215.2)	32.1(12.3-79.7)	0.021

---

$T_{max}>10s$ , mL	40.7(9.1-133.9)	6.4(0.4-28.2)	0.003
$T_{max}>10s$ / $T_{max}>8s$	0.6(0.3-0.8)	0.3(0.2-0.4)	<0.001
$T_{max}>10s$ / $T_{max}>6s$	0.3(0.1-0.6)	0.1(0.0-0.2)	0.001
$T_{max}>10s$ / $T_{max}>4s$	0.1(0.1-0.4)	0.0(0.0-0.1)	0.001
$T_{max}>8s$ / $T_{max}>6s$	0.6(0.3-0.8)	0.4(0.2-0.5)	0.004
$T_{max}>8s$ / $T_{max}>4s$	0.3(0.1-0.5)	0.1(0.1-0.2)	0.003
$T_{max}>6s$ / $T_{max}>4s$	0.6(0.5-0.8)	0.4(0.3-0.6)	0.001
Stroke etiologies			0.561
LAA	21(72.4%)	27(79.4%)	
CE	6(20.7%)	3(8.8%)	
Dissection	1(3.4%)	2(5.9%)	
Undetermined	1(3.4%)	2(5.9%)	

---

NIHSS: National Institutes of Health Stroke Scale; ASPECTS: Alberta Stroke Program Early CT Score;  $T_{max}$ : time-to-peak of the residual function; LAA: large-artery atherosclerosis; CE: cardioembolism;

**Table 2 Ability of Perfusion Lesion to Discriminate Neurological Deterioration in Patients with Symptomatic Isolated Internal Carotid Artery Occlusion before Endovascular Thrombectomy**

Variables	AUC (95% CI)	Cut off	Sensitivity	Specificity	Youden index	P value
Baseline infarct core volume	0.691(0.555-0.826)	2.9mL	62.1%	79.4%	41.5%	0.006
Hypoperfusion profiles						
$T_{max}>4s$ , mL	0.581(0.434-0.728)	424.5mL	31.0%	91.2%	22.2%	0.278
$T_{max}>6s$ , mL	0.656(0.514-0.798)	164.2mL	65.5%	73.5%	39.0%	0.031
$T_{max}>8s$ , mL	0.670(0.532-0.809)	46.7mL	69.0%	67.6%	36.6%	0.016
$T_{max}>10s$ , mL	0.716(0.587-0.845)	27.0mL	62.1%	76.5%	38.6%	0.001
$T_{max}>10s / T_{max}>8s$	0.762(0.640-0.883)	0.3	89.7%	56.3%	46.0%	<0.001
$T_{max}>10s / T_{max}>6s$	0.753(0.632-0.875)	0.2	72.4%	72.7%	45.1%	<0.001
$T_{max}>10s / T_{max}>4s$	0.751(0.628-0.873)	0.1	79.3%	64.7%	44.0%	<0.001
$T_{max}>8s / T_{max}>6s$	0.713(0.583-0.842)	0.4	69.0%	66.7%	35.7%	0.001
$T_{max}>8s / T_{max}>4s$	0.720(0.628-0.873)	0.2	65.5%	76.5%	42.0%	0.001
$T_{max}>6s / T_{max}>4s$	0.751(0.624-0.877)	0.5	79.3%	70.6%	49.9%	<0.001

$T_{max}$ : time-to-peak of the residual function; AUC: area under the curve.

**Table 3 Comparison of Characteristics between Symptomatic Isolated Internal Carotid Artery Occlusion Patients Undergoing Endovascular Treatment with Good Outcome and Poor outcome**

	Poor Outcome (n = 34)	Good Outcome (n = 23)	P value
Age, y	67(54-78)	64(58-68)	0.563
Male	23(67.6%)	18(78.3%)	0.382
Baseline NIHSS	11(7-14)	7(6-9)	0.010
Systolic blood pressure, mmHg	150(126-161)	145(125-158)	0.841
Diastolic blood pressure, mmHg	78(69-90)	78(68-86)	0.484
Intravenous thrombolysis	3(8.8%)	4(17.4%)	0.423
Prior antiplatelet use	5(14.7%)	2(8.7%)	0.689
Prior anticoagulants use	0(0.0%)	0(0.0%)	-
Risk factors			
Smoking	15(44.1%)	9(39.1%)	0.708
Hypertension	24(70.6%)	15(65.2%)	0.669
Diabetes mellitus	15(44.1%)	7(30.4%)	0.298
History of stroke or transient ischemic attack	3(8.8%)	1(4.3%)	0.641
Hyperlipidaemia	4(11.8%)	2(8.7%)	1.000
Atrial fibrillation	5(14.7%)	1(4.3%)	0.385
Baseline ASPECTS	8(7-9)	9(7-10)	0.088
Neurological deterioration	18(52.9%)	15(65.2%)	0.357
Onset-to-puncture time, min	975(597-1736)	1045(692-2460)	0.375
Recanalization	30(88.2%)	23(100%)	0.140
Stent implantation	16(47.1%)	10(43.5%)	0.790
Hemorrhagic transformation	8(23.5%)	2(8.7%)	0.178
Baseline perfusion lesion			
Baseline infarct core volume	0.5(0.0-18.7)	0.0(0.0-3.3)	0.364

---

Hypoperfusion profiles			
$T_{max}>4s$ , mL	309.0(218.0-412.1)	189.3(62.0-363.2)	0.053
$T_{max}>6s$ , mL	164.2(69.5-269.4)	55.7(16.3-169.0)	0.006
$T_{max}>8s$ , mL	66.4(23.8-151.4)	14.7(3.3-75.5)	0.007
$T_{max}>10s$ , mL	19.9(5.8-84.1)	3.3(0.0-19.0)	0.009
$T_{max}>10s / T_{max}>8s$	0.4(0.2-0.7)	0.3(0.1-0.5)	0.145
$T_{max}>10s / T_{max}>6s$	0.2(0.1-0.5)	0.1(0.0-0.3)	0.068
$T_{max}>10s / T_{max}>4s$	0.1(0.0-0.3)	0.0(0.0-0.1)	0.034
$T_{max}>8s / T_{max}>6s$	0.4(0.3-0.7)	0.3(0.2-0.6)	0.100
$T_{max}>8s / T_{max}>4s$	0.2(0.1-0.5)	0.1(0.1-0.2)	0.033
$T_{max}>6s / T_{max}>4s$	0.5(0.3-0.7)	0.4(0.2-0.6)	0.037
Stroke etiologies			0.619
LAA	25(73.5%)	18(78.3%)	
CE	6(17.6%)	2(8.7%)	
Dissection	1(2.9%)	2(8.7%)	
Undetermined	2(5.9%)	1(4.3%)	

---

NIHSS: National Institutes of Health Stroke Scale; ASPECTS: Alberta Stroke Program Early CT Score;  $T_{max}$ : time-to-peak of the residual function; LAA: large-artery atherosclerosis; CE: cardioembolism;

**Table 4 Ability of Perfusion Lesion to Discriminate Neurological Outcome in Patients with Symptomatic Isolated Internal Carotid Artery Occlusion after Endovascular Thrombectomy**

Variable	AUC (95% CI)	Cut off	Sensitivity	Specificity	Youden index	P value
Baseline infarct core volume	0.566(0.417-0.716)	5.3mL	44.1%	82.6%	26.7%	0.384
Hypoperfusion profiles						
T <sub>max</sub> >4s, mL	0.652(0.499-0.805)	166.7mL	91.2%	47.8%	39.0%	0.053
T <sub>max</sub> >6s, mL	0.715(0.575-0.854)	64.9mL	82.4%	60.9%	43.3%	0.006
T <sub>max</sub> >8s, mL	0.712(0.571-0.853)	18.3mL	85.3%	56.5%	41.8%	0.007
T <sub>max</sub> >10s, mL	0.706(0.564-0.848)	3.8mL	85.3%	56.5%	41.8%	0.009
T <sub>max</sub> >10s / T <sub>max</sub> >8s	0.618(0.467-0.769)	0.7	26.5%	95.2%	21.7%	0.146
T <sub>max</sub> >10s / T <sub>max</sub> >6s	0.645(0.498-0.793)	0.1	61.8%	68.2%	30.0%	0.069
T <sub>max</sub> >10s / T <sub>max</sub> >4s	0.666(0.522-0.810)	0.0	79.4%	52.2%	31.6%	0.034
T <sub>max</sub> >8s / T <sub>max</sub> >6s	0.631(0.483-0.779)	0.4	67.6%	59.1%	26.7%	0.100
T <sub>max</sub> >8s / T <sub>max</sub> >4s	0.668(0.523-0.812)	0.1	82.4%	47.8%	30.2%	0.033
T <sub>max</sub> >6s / T <sub>max</sub> >4s	0.664(0.522-0.806)	0.5	55.9%	73.9%	29.8%	0.037

T<sub>max</sub>: time-to-peak of the residual function; AUC: area under the curve.